U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07486934) titled 'Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1' on March 17.
Brief Summary: The purpose of the study is to assess the efficacy, safety, and tolerability of DYNE-101 for the treatment of myotonic dystrophy 1 (DM1).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Myotonic Dystrophy Type 1 (DM1)
DM1
Myotonic Dystrophy
Steinert Disease
Steinert
Intervention:
DRUG: DYNE-101
Administered by IV infusion
DRUG: Placebo
Administered by IV infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Dyne Therapeutics
Published by HT Digital Content Services with permis...